Click here to view online. Add this email to your safelist.
Farxiga granted Fast Track Designation in the US for heart failure following acute myocardial infarction leveraging an innovative registry-based trial design
16 July 2020
AstraZeneca has been granted Fast Track Designation in the US for the development of Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) or cardiovascular (CV) death in adults following an acute myocardial infarction (MI) or heart attack.
|
|||||
|
|||||
|
For more information please visit astrazeneca.com. If you would like to unsubscribe please click here. |
